Consonance Capital Management LP
- SEC CIK
- 0001544773
- Latest filing
- Nov 14, 2022
The latest 13F from Consonance Capital Management LP covers Q3 2022 (filed Nov 14, 2022): 2 long positions worth $7.28M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Surrozen, Inc. (SRZN) at 97.0%. Livermore has 7 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q3 2022
Share counts compared with Q2 2022: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 0
- Added
- 0
- Reduced
- 0
- Sold out
- 5
- Est. −$13.0M
Top 5 holdings
Share of this quarter's portfolio value
- SRZNSurrozen, Inc.
- Surrozen, Inc.86889P1173.0%$215.0K
Biggest buys
New and added positions, by estimated amount bought
None this quarter.
Largest weight increases
New and added positions, by percentage points of the portfolio gained
None this quarter.
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
Metrics
13F metrics for Q3 2022, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $7.28M
- −$16.4M (−69.3%) vs. prior quarter
- Positions
- 2
- −5 vs. prior quarter
- Top 10 concentration
- 100.0%
- Top 10 as share of value
- Turnover
- 0.0%
- Q3 2022, one quarter
- Average holding period
- 5.0 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
7 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $938.0M (Q1 2021)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q3 2022 | Nov 14, 2022 | 2 | $7.28M | SRZNSurrozen, Inc. | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 15, 2022 | 7 | $23.7M | SRZNSLNCMPX | vs. Q1 2022 | SEC |
| Q1 2022 | May 16, 2022 | 8 | $58.9M | TNDMSLNSRZN | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 14, 2022 | 15 | $153.3M | TNDMGMEDSRZN | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 15, 2021 | 17 | $182.7M | TNDMGMEDUTHR | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 16, 2021 | 32 | $830.9M | PTGXSWTXTNDM | vs. Q1 2021 | SEC |
| Q1 2021 | May 17, 2021 | 35 | $938.0M | UTHRSWTXMGNX | – | SEC |
13D and 13G filings
Companies where Consonance Capital Management LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
Consonance Capital Management LP does not currently report owning 5% or more of any company.
Latest filings
56 filings on file made by Consonance Capital Management LP or listing it as a reporting person; the latest 20 are shown.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| SRZNSurrozen, Inc. | Dec 15, 2022 | 13D/AOld format | – | – | – | SEC |
| CLRBCellectar Biosciences, Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| SIOXSio Gene Therapies Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| PTGXProtagonist Therapeutics, Inc | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| GenMark Diagnostics, Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| GMDAGamida Cell Ltd. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| CASICASI Pharmaceuticals, Inc (DE) | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| ASMBAssembly Biosciences, Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| ADMAAdma Biologics, Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| SRZNSurrozen, Inc. | Sep 29, 2021 | 13D/AOld format | – | – | – | SEC |
| SRZNSurrozen, Inc. | Aug 18, 2021 | 13D/AOld format | – | – | – | SEC |
| SRZNSurrozen, Inc. | Apr 27, 2021 | 13D/AOld format | – | – | – | SEC |
| Oxford Immunotec Global PLC | Feb 17, 2021 | 13G/AOld format | – | – | – | SEC |
| OVIDOvid Therapeutics Inc. | Feb 17, 2021 | 13G/AOld format | – | – | – | SEC |
| Liminal BioSciences Inc. | Feb 17, 2021 | 13G/AOld format | – | – | – | SEC |
| KPTIKaryopharm Therapeutics Inc. | Feb 17, 2021 | 13G/AOld format | – | – | – | SEC |
| KDMNKadmon Holdings, Inc. | Feb 17, 2021 | 13G/AOld format | – | – | – | SEC |
| ISEEIVERIC bio, Inc. | Feb 17, 2021 | 13G/AOld format | – | – | – | SEC |
| GenMark Diagnostics, Inc. | Feb 17, 2021 | 13GOld format | – | – | – | SEC |
| GMDAGamida Cell Ltd. | Feb 17, 2021 | 13GOld format | – | – | – | SEC |